MX349387B - Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad. - Google Patents

Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Info

Publication number
MX349387B
MX349387B MX2012001967A MX2012001967A MX349387B MX 349387 B MX349387 B MX 349387B MX 2012001967 A MX2012001967 A MX 2012001967A MX 2012001967 A MX2012001967 A MX 2012001967A MX 349387 B MX349387 B MX 349387B
Authority
MX
Mexico
Prior art keywords
desferrioxamine
immune
metal complexes
treatment
dfo
Prior art date
Application number
MX2012001967A
Other languages
English (en)
Other versions
MX2012001967A (es
Inventor
Chevion Mordechai
Vinokur Vladimir
Berenshtein Eduard
Eliashar Ron
Bulvik Baruch
Original Assignee
Chevion Mordechai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chevion Mordechai filed Critical Chevion Mordechai
Publication of MX2012001967A publication Critical patent/MX2012001967A/es
Publication of MX349387B publication Critical patent/MX349387B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos, kits y composiciones combinadas que utilizan complejos de DFO-metal, especialmente, complejos de zinc-desferroxiamina (Zn-DFO), galio-desferroxiamina (Ga-DFO) y cualquier combinación de los mismos para prevenir tratar, mejorar o inhibir un trastorno relacionado con la inmunidad, especialmente, un trastorno inflamatorio relacionado con la piel tal como psoriasis, una condición respiratoria inflamatoria tal como asma, y una enfermedad autoinmunitaria tal como diabetes y cualquier trastorno relacionado con la inmunidad.
MX2012001967A 2009-08-19 2010-08-19 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad. MX349387B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23506209P 2009-08-19 2009-08-19
US29859610P 2010-01-27 2010-01-27
US34761710P 2010-05-24 2010-05-24
PCT/IL2010/000681 WO2011021203A2 (en) 2009-08-19 2010-08-19 Desferrioxamine-metal complexes for the treatment of immune-related disorders

Publications (2)

Publication Number Publication Date
MX2012001967A MX2012001967A (es) 2012-07-17
MX349387B true MX349387B (es) 2017-07-05

Family

ID=43259672

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001967A MX349387B (es) 2009-08-19 2010-08-19 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.
MX2017009091A MX2017009091A (es) 2009-08-19 2012-02-14 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017009091A MX2017009091A (es) 2009-08-19 2012-02-14 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Country Status (10)

Country Link
US (2) US8975294B2 (es)
EP (2) EP2467135B1 (es)
JP (1) JP2013502407A (es)
CN (1) CN102573831A (es)
AU (2) AU2010286054B2 (es)
BR (1) BR112012003447A2 (es)
CA (1) CA2771257C (es)
IL (1) IL253293B (es)
MX (2) MX349387B (es)
WO (1) WO2011021203A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
JP2013123450A (ja) * 2011-12-13 2013-06-24 Akihiro Sato 金属錯体イオン液を応用した塵肺の療養方法、および、咽頭・気管・気管支の療養方法
DK3236970T3 (da) * 2014-12-22 2021-01-18 Mordechai Chevion Nye metalkomplekser af nocardamin og deres anvendelse i farmakologiske sammensætninger
KR20180105701A (ko) 2016-02-11 2018-09-28 모데차이 체비온 신경변성의 치료를 위한 방법 및 약학 조성물
WO2018039488A1 (en) * 2016-08-24 2018-03-01 Wisconsin Alumni Research Foundation Siderophore-polymer conjugates for increasing bacterial sensitivity to antibiotics
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
KR20200143403A (ko) * 2018-03-27 2020-12-23 타우토나 그룹 아이피 홀딩 컴퍼니 엘엘씨 만성 창상을 예방하고 치료하기 위한 철분 킬레이터의 국소 및 경피 전달
CA3096986A1 (en) * 2018-04-13 2019-10-17 Mordechai Chevion Compositions and methods for treatment of demyelination
US20210161840A1 (en) * 2018-04-15 2021-06-03 Mordechai Chevion Compositions and methods for treatment of iron overload
CN115279394A (zh) * 2019-11-20 2022-11-01 斯坦福大学托管董事会 用于放射治疗的预防性皮肤治疗
WO2022015983A1 (en) * 2020-07-15 2022-01-20 Memorial Sloan-Kettering Cancer Center Methods of treating leptomeningeal metastasis
CN114460163B (zh) * 2022-02-11 2023-03-03 河北师范大学 一种检测生物组织铁含量的maldi质谱成像方法
US20240079111A1 (en) * 2022-08-24 2024-03-07 Insulet Corporation System and method for adjusting insulin delivery to account for insulin resistance

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
IL91047A (en) * 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
IL106064A (en) * 1993-06-18 1997-11-20 Yissum Res Dev Co Gallium complexes for the treatment of free radical-induced diseases
AU6031096A (en) * 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
CA2206203A1 (en) * 1997-05-27 1998-11-27 University Of British Columbia Photoactivation of endogenous porphyrins for treatment of psoriasis
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
FR2825920B1 (fr) 2001-06-15 2006-04-28 Oreal Desferal comme inhibiteur de no-synthase et utilisations
WO2004060490A1 (en) * 2003-01-07 2004-07-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent
EP1648376A2 (en) * 2003-06-04 2006-04-26 Ebersytes, LLC Novel dermatological composition
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US8680148B2 (en) * 2006-08-11 2014-03-25 University Of Washington Metallo-desferrioxamine complexes and their use in the treatment of bacterial infections
WO2008061299A1 (en) * 2006-11-21 2008-05-29 Garvan Institute Of Medical Research Method of treating diabetes

Also Published As

Publication number Publication date
AU2010286054A1 (en) 2012-03-08
EP2467135A2 (en) 2012-06-27
US20120220651A1 (en) 2012-08-30
IL253293A0 (en) 2017-09-28
BR112012003447A2 (pt) 2018-03-20
EP2467135B1 (en) 2017-02-01
WO2011021203A3 (en) 2011-04-14
MX2017009091A (es) 2021-03-25
AU2010286054B2 (en) 2016-10-27
EP3189836A2 (en) 2017-07-12
EP3189836B1 (en) 2024-01-17
US20150148413A1 (en) 2015-05-28
EP3189836A3 (en) 2017-09-27
WO2011021203A2 (en) 2011-02-24
CA2771257A1 (en) 2011-02-24
JP2013502407A (ja) 2013-01-24
CA2771257C (en) 2018-09-18
MX2012001967A (es) 2012-07-17
AU2016244189A1 (en) 2016-10-27
IL253293B (en) 2020-01-30
AU2016244189B2 (en) 2018-06-28
US8975294B2 (en) 2015-03-10
CN102573831A (zh) 2012-07-11
US9770430B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
MX2017009091A (es) Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.
EA020330B3 (ru) Хиназолиновые соединения
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
SG179038A1 (en) Compositions and methods for diagnosing autism spectrum disorders
MY165582A (en) Azetidine and cyclobutane derivatives as jak inhibitors
IN2012DN02081A (es)
PH12017500864A1 (en) Anti-notch1 antibodies
UA115983C2 (uk) Інгібітори днк-пк
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
MA32889B1 (fr) Composes de pyrazine comme inhibiteurs de phosphodiesterase 10
IN2012DN00624A (es)
MX355325B (es) Quinazolincarboxamida azetidinas.
WO2010006130A3 (en) Pde-10 inhibitors
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
IN2015KN00492A (es)
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: MORDECHAI CHEVION